[Featured Stock] Sinopex Rises on Success of Korea's First Artificial Kidney Dialysis Clinical Trial
Sinopex's stock price is showing strong performance in early trading. The news of successfully completing clinical trials for the blood filter (dialysis) used in artificial kidneys for the first time in Korea is believed to have driven the stock price up.
As of 9:10 AM on the 7th, Sinopex is trading at 5,410 KRW, up 11.32% (550 KRW) compared to the previous session.
Sinopex announced through a press release that the patient-use clinical trial conducted on 50 hemodialysis patients at five major hospitals in Korea was successfully completed last week. This is the first official clinical trial conducted with a domestically produced blood dialysis filter for artificial kidneys, marking 59 years since hemodialysis began in Korea.
Hot Picks Today
"Why Live in Seoul When You Can Pay Half Here?" 30 Minutes to Gangnam... Private Sales Begin in Gyeyang New Town
- "Living Becomes Easier Thanks to SK Hynix, But Conservative U.S. Cities Remain Torn Inside [U.S. Midterm Election D-40]②-2"
- "I Went for the Cheap Coffee, but Now I Feel Uneasy"... Major Coffee Franchises Cited for Violations One After Another
- A 30-Dollar Painting No One Bought Turns Out to Be a 250,000-Dollar 'Original' Thanks to a Signature
- "After Spending 170,000 Won on Hanwoo, This Is What I Got": Why Webtoon Artist Kim Gyusam Decided to Give Cash Instead
Currently, blood filters for artificial kidneys are entirely imported under duty-free conditions, but Sinopex has succeeded in domestic production and obtained product approval from the Ministry of Food and Drug Safety in March last year.
![[Featured Stock] Sinopex Rises on Success of Korea's First Artificial Kidney Dialysis Clinical Trial](http://www.asiae.co.kr/news/img_view.htm?img=2025030509433154739_1741135411.jpg)
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.
